GLP-1 Receptor Agonists Show No Increased Postoperative Complications in Hand Surgery, but Gaps Remain
Background
The escalating use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes mellitus (T2DM) and obesity presents a growing challenge in perioperative care, particularly in hand surgery. Concerns about delayed gastric emptying and increased aspiration risk have led to clinical uncertainty and evolving guideline recommendations. A clear understanding of GLP-1 RA pharmacology and its impact on surgical outcomes, bone healing, and wound healing in this patient population is crucial but currently lacking, creating a significant knowledge gap for safe perioperative management.
Study Design
This review article synthesized current concepts and evolving guideline recommendations concerning perioperative management of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in hand surgery patients. It systematically examined existing literature to consolidate evidence on potential risks like delayed gastric emptying and aspiration, as well as the impact on surgical outcomes. The authors aimed to provide a comprehensive overview for clinicians navigating the increasing prevalence of GLP-1 RA use, including agents such as semaglutide and tirzepatide, in this specific surgical population.
Results
The review found that despite initial concerns regarding delayed gastric emptying and aspiration risk, current evidence from multiple studies reports no notable increase in postoperative complications among hand surgery patients taking GLP-1 RAs. Potential benefits, such as reduced systemic medical morbidity and improved metabolic control, may even contribute to favorable surgical outcomes. These benefits are likely mediated through improved metabolic markers and reduced systemic inflammation. The GLP-1R activation by these agonists can influence various physiological processes beyond glucose regulation.
However, the medical literature on GLP-1 RA effects specifically in hand and orthopedic surgery remains substantially limited, leaving critical questions unanswered. These include optimal perioperative medication management strategies, the impact of rapid weight loss on bone and wound healing, and specific anesthesia-related risks. While semaglutide and tirzepatide are widely used, comprehensive data for these specific agents in this context are still developing.
Key Findings
- Current evidence suggests no notable increase in postoperative complications for hand surgery patients on GLP-1 RAs.
- Potential benefits of GLP-1 RAs in surgical outcomes may exist due to improved metabolic control and reduced morbidity.
- Significant limitations exist in the medical literature regarding GLP-1 RA use in hand and orthopedic surgery.
- Unanswered questions include optimal perioperative medication management and effects on bone/wound healing.
- Hand surgeons require a strong understanding of GLP-1 RA pharmacology for individualized patient care.
Why It Matters
This review highlights that current data, though limited, generally supports the safety of GLP-1 RA use in the perioperative period for hand surgery, suggesting no notable increase in complications. Hand surgeons must understand GLP-1 RA pharmacology and emerging evidence to guide individualized decision-making for patients. While the immediate concern of increased aspiration risk appears mitigated by current findings, significant gaps remain regarding optimal perioperative protocols, especially concerning medication hold times, and the long-term effects on bone and wound healing in the context of rapid weight loss. Further research is needed to establish definitive guidelines and potentially leverage the metabolic benefits of GLP-1 RAs to improve surgical outcomes.
glp-1-ra
semaglutide
tirzepatide
hand-surgery
perioperative-care
obesity